BioNTech SE (NASDAQ:BNTX – Get Rating) – Research analysts at SVB Leerink dropped their Q3 2022 EPS estimates for BioNTech in a research report issued on Tuesday, August 9th. SVB Leerink analyst D. Graybosch now forecasts that the company will post earnings per share of $2.32 for the quarter, down from their prior forecast of $2.50. SVB Leerink currently has a "Outperform" rating and a $224.00 target price on the stock. The consensus estimate for BioNTech's current full-year earnings is $34.43 per share. SVB Leerink also issued estimates for BioNTech's Q2 2023 earnings at $4.98 EPS, Q4 2023 earnings at $6.73 EPS, Q2 2024 earnings at $0.59 EPS, FY2024 earnings at $3.48 EPS, FY2025 earnings at $7.76 EPS and FY2026 earnings at $9.64 EPS.

A number of other equities analysts have also recently commented on BNTX. JPMorgan Chase & Co. set a $183.00 price objective on shares of BioNTech in a research report on Tuesday, May 10th. Canaccord Genuity Group reissued a "buy" rating and set a $192.00 target price on shares of BioNTech in a report on Wednesday, July 6th. Berenberg Bank set a $312.00 target price on BioNTech in a report on Tuesday. Canaccord Genuity Group lifted their target price on BioNTech from $192.00 to $200.00 and gave the stock a "buy" rating in a report on Tuesday. Finally, Deutsche Bank Aktiengesellschaft set a $180.00 target price on BioNTech in a report on Friday, July 1st. Six equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $235.62.

BioNTech Trading Up 2.4 %

BioNTech (NASDAQ:BNTX – Get Rating) last released its earnings results on Monday, August 8th. The company reported $6.45 earnings per share for the quarter, missing the consensus estimate of $7.08 by ($0.63). BioNTech had a net margin of 55.13% and a return on equity of 122.24%. The firm had revenue of $3.20 billion during the quarter, compared to the consensus estimate of $4.11 billion. During the same period in the prior year, the business posted $12.98 earnings per share. BioNTech's quarterly revenue was down 39.8% compared to the same quarter last year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Mackenzie Financial Corp raised its stake in BioNTech by 206.8% during the second quarter. Mackenzie Financial Corp now owns 4,753 shares of the company's stock worth $709,000 after acquiring an additional 3,204 shares in the last quarter. Boston Common Asset Management LLC raised its stake in BioNTech by 1.3% during the second quarter. Boston Common Asset Management LLC now owns 283,776 shares of the company's stock worth $42,311,000 after acquiring an additional 3,595 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp raised its stake in BioNTech by 13.0% during the second quarter. Mitsubishi UFJ Trust & Banking Corp now owns 250,410 shares of the company's stock worth $37,336,000 after acquiring an additional 28,810 shares in the last quarter. Pictet Asset Management SA raised its stake in BioNTech by 18.4% during the second quarter. Pictet Asset Management SA now owns 626,089 shares of the company's stock worth $93,350,000 after acquiring an additional 97,247 shares in the last quarter. Finally, Foster & Motley Inc. acquired a new position in BioNTech during the second quarter worth about $463,000. Institutional investors and hedge funds own 14.42% of the company's stock.

About BioNTech

(Get Rating)

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.

Featured Articles

• Get a free copy of the StockNews.com research report on BioNTech (BNTX)
• Could Rite Aid Be an Acquisition Target, Again?
• The How And Why of Investing in Oil Stocks
• The How and Why of Investing in Gold Stocks
• A Rounded Bottom In Draftkings, Inc Begins To Reverse Course
• Workhorse Group Is Ready To Get Back On The Horse

Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.